Reuters logo
BRIEF-Astellas and Affinivax announce worldwide partnership for maps vaccine targeting pneumococcal disease
February 28, 2017 / 5:25 AM / 7 months ago

BRIEF-Astellas and Affinivax announce worldwide partnership for maps vaccine targeting pneumococcal disease

Feb 28 (Reuters) - Astellaas Pharma Inc :

* Says Affinivax, Inc. and Astellas Pharma Inc. entered into an exclusive worldwide license agreement to develop and commercialize a vaccine targeting Streptococcus pneumoniae

* Says the partnership will utilize Affinivax’s proprietary vaccine technology platform – Multiple Antigen Presenting System (MAPS) – to advance a novel MAPS vaccine targeted to prevent and reduce the spread of pneumococcal disease

Source text in Japanese:goo.gl/mAebjo

Further company coverage: (Beijing Headline News)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below